Key facts
- This page summarizes Michael A. Metzger's Form 4 filing for CTI BIOPHARMA CORP.
- 6 reported transactions and 6 derivative rows are listed below.
- Accepted by SEC: 26 Jun 2023, 16:05.
Michael A. Metzger - 26 Jun 2023 Form 4 Insider Report for CTI BIOPHARMA CORP
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 26 Jun 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 26 Jun 2023, 16:05:23 UTC
- Prior SEC filing
- 07 Apr 2023
- Next SEC filing
- 09 Feb 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Adam R. Craig, attorney-in-fact for Michael A. Metzger
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Michael A. Metzger filed Form 4 for CTI BIOPHARMA CORP on 26 Jun 2023.
Change
- Previous filing in this sequence was filed on 07 Apr 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CTIC
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -50,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 26 Jun 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 50,000
- Exercise price
- $4.25
- Footnotes
- F1, F2
CTIC
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -60,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 26 Jun 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 60,000
- Exercise price
- $4.61
- Footnotes
- F1, F2
CTIC
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -63,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 26 Jun 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 63,000
- Exercise price
- $1.00
- Footnotes
- F1, F2
CTIC
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -80,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 26 Jun 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 80,000
- Exercise price
- $3.30
- Footnotes
- F1, F2
CTIC
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -80,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 26 Jun 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 80,000
- Exercise price
- $4.49
- Footnotes
- F1, F2
CTIC
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -80,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 26 Jun 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 80,000
- Exercise price
- $4.08
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Michael A. Metzger is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 2 footnotes
Footnote F1
Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes)
Footnote F2
(Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option.